trimethoprim--sulfamethoxazole-drug-combination has been researched along with tafenoquine* in 2 studies
2 other study(ies) available for trimethoprim--sulfamethoxazole-drug-combination and tafenoquine
Article | Year |
---|---|
Efficacy of intermittent dosage of 8-aminoquinolines for therapy or prophylaxis of Pneumocystis pneumonia in rats.
Experimental 8-aminoquinolines from Walter Reed Army Institute for Research are effective for prophylaxis or therapy of Pneumocystis carinii pneumonia in rat models. In the present study, primaquine, WR6026, and WR238605 were tested in prophylaxis and treatment models of P. carinii pneumonia to compare the effectiveness of continuous versus intermittent dosing. For treatment of P. carinii pneumonia, the drugs showed detectable effects when given once every 4 days (primaquine and WR6026 at doses greater than 8 mg/kg; WR238605 at doses greater than 2 mg/kg). For prophylaxis, WR6026 and WR238605 were effective given alone daily (WR6026 at doses greater than 0.25 mg/kg; WR238605 at doses greater than 0.57 mg/kg). WR6026 and WR238605 at 4 mg/kg given once every 4 days for prophylaxis were as effective as daily trimethoprim-sulfamethoxazole. These studies suggest that higher doses of 8-aminoquinolines administered at appropriate intervals may be as effective as continuous dosing for prophylaxis of P. carinii pneumonia. Topics: Aminoquinolines; Animals; Clindamycin; Disease Models, Animal; Drug Administration Schedule; Female; Pneumonia, Pneumocystis; Primaquine; Rats; Rats, Inbred Strains; Specific Pathogen-Free Organisms; Trimethoprim, Sulfamethoxazole Drug Combination | 1992 |
Inoculated mouse model of Pneumocystis carinii infection.
A transtracheally inoculated mouse model of Pneumocystis carinii has been developed using BALB/c mice. The advantage of this strain of mice include that they are widely available, inexpensive, and were not infected with Pneumocystis before inoculation. Inoculated mice that were not treated had a mean infectivity score of 4.1 compared with inoculated mice treated with the effective anti-Pneumocystis drug combination of trimethoprim plus sulfamethoxazole, which had a mean infectivity score of 0.1, an approximately 4 log difference. The inoculated BALB/c mouse provides a model to serve as a valuable addition to rat models currently used, providing a source of organisms from a different host for cross-species comparisons and for studies of drug efficacy for therapy and prophylaxis. The inoculated mouse is especially cost effective and allows testing of compounds in short supply. Topics: Aminoquinolines; Animals; Antimalarials; Clindamycin; Dexamethasone; Disease Models, Animal; Drug Therapy, Combination; Immunosuppression Therapy; Mice; Mice, Inbred BALB C; Pneumocystis Infections; Primaquine; Trimethoprim, Sulfamethoxazole Drug Combination | 1992 |